According to a KFF analysis, nearly 3.8 million Medicare beneficiaries are potentially eligible for the newly introduced Medicare GLP-1 Bridge program. This program aims to provide coverage for GLP-1 medications that are used for weight loss.
Eligibility for the program is determined by specific criteria that beneficiaries must meet. The initiative reflects a shift in Medicare's coverage policies regarding weight loss treatments.
It is important to note that this program is temporary and may be subject to changes as Medicare policies evolve. The findings were published based on claims data from 2023.